Daily rifapentine for treatment of pulmonary tuberculosis: A randomized, dose-ranging trial

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 3, 2015, Pages 333-343

  Dorman, Susan E ^a   Savic, Radojka M ^b   Goldberg, Stefan ^c   Stout, Jason E ^d   Schluger, Neil ^e   Muzanyi, Grace ^f   Johnson, John L ^f,g   Nahid, Payam ^b   Hecker, Emily J ^d   Heilig, Charles M ^c   Bozeman, Lorna ^c   Feng, Pei Jean I ^c   Moro, Ruth N ^c,h   MacKenzie, William ^c   Dooley, Kelly E ^a   Nuermberger, Eric L ^a   Vernon, Andrew ^c   Weiner, Marc ⁱ  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Department of Medicine   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CDC FOUNDATION   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Mycobacterium; Rifamycins; Rifapentine; Therapeutics; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LIQUID CULTURE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM CULTURE; SPUTUM SMEAR; TREATMENT DURATION; ADOLESCENT; AFRICA; AGED; ANALOGS AND DERIVATIVES; ASIA; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; EUROPE; FEMALE; MALE; MIDDLE AGED; NORTH AMERICA; SINGLE BLIND PROCEDURE; SOUTH AMERICA; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

ADOLESCENT; ADULT; AFRICA; AGED; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; ASIA; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; NORTH AMERICA; RIFAMPIN; SINGLE-BLIND METHOD; SOUTH AMERICA; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84922287357     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201410-1843OC     Document Type: Article

References (47)

1. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM Jr, Dye C, Halloran ME. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci USA 2009;106:13980-13985.
2. Grosset J. Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin Chest Med 1980;1:231-241.
3. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000;4:796-806.
4. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003;47:2118-2124.
5. Ji B, Truffot-Pernot C, Lacroix C, Raviglione MC, O'Brien RJ, Olliaro P, Roscigno G, Grosset J. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993;148:1541-1546.
6. Long MW, Snider DE Jr, Farer LS. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979;119:879-894.
7. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121:939-949.
8. Sirgel FA, Fourie PB, Donald PR, Padayatchi N, Rustomjee R, Levin J, Roscigno G, Norman J, McIlleron H, Mitchison DA. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 2005;172:128-135.
9. Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H, Maritz JS, Donald PR. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2007;51:2994-2996.
10. van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen G, Gillespie SH, Boeree MJ. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis 2011;52:e194-e199.
11. Heifets LB, Lindholm-Levy PJ, Flory MA. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis 1990;141:626-630.
12. Keung A, Eller MG, McKenzie KA, Weir SJ. Single and multiple dose pharmacokinetics of rifapentine in man: part II. Int J Tuberc Lung Dis 1999;3:437-444.
13. Langdon G, Wilkins JJ, Smith PJ, McIlleron H. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. Int J Tuberc Lung Dis 2004;8:862-867.
14. Bemer-Melchior P, Bryskier A, Drugeon HB. Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. J Antimicrob Chemother 2000;46:571-576.
15. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40:327-341.
16. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007;4:e344.
17. Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med 2008;178: 989-993.
18. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 2012;56:4331-4340.
19. Dooley KE, Bliven-Sizemore EE, Weiner M, Lu Y, Nuermberger EL, Hubbard WC, Fuchs EJ, Melia MT, Burman WJ, Dorman SE. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther 2012;91:881-888.
20. Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, et al.; Tuberculosis Trials Consortium. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis 2012;206:1030-1040.
21. Dorman S; CDC Tuberculosis Trials Consortium. A dose-ranging study of daily rifapentine-containing regimens for intensive phase treatment of pulmonary TB: Tuberculosis Trials Consortium Study 29X. Presented at the 44th Union World Conference on Lung Health. November 2, 2013, Paris, France. Abstract OP-230-02.
22. Soares JF, Wu CFJ. Some restricted randomization rules in sequential designs. Commun Stat Theory Methods 1983;12:2017-2034.
23. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, et al.; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
24. Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 1999;115:12-18.
25. Zvada SP, Van Der Walt JS, Smith PJ, Fourie PB, Roscigno G, Mitchison D, Simonsson US, McIlleron HM. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrob Agents Chemother 2010;54:3390-3394.
26. Weiner M, Bock N, Peloquin CA, Burman WJ, Khan A, Vernon A, Zhao Z, Weis S, Sterling TR, Hayden K, et al.; Tuberculosis Trials Consortium. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med 2004;169:1191-1197.
27. Savic RM, Lu Y, Bliven-Sizemore E, Weiner M, Nuermberger E, Burman W, Dorman SE, Dooley KE. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother 2014;58:3035-3042.
28. Savic RM, Weiner M, Mac Kenzie W. PKPD analysis of rifapentine in patients during intensive phase treatment for tuberculosis from Tuberculosis Trial Consortium Studies 29 and 29x. Presented at the 6th International Workshop on Clinical Pharmacology of Tuberculosis Drugs. September 9, 2013, Denver, CO. Abstract 11.
29. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-338.
30. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, et al.; Tuberculosis Trials Consortium. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009;180:273-280.
31. Clopper C, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-413.
32. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17:857-872.
33. Sun J. A non-parametric test for interval-censored failure time data with application to AIDS studies. Stat Med 1996;15:1387-1395.
34. Fay MP, Shaw PA. Exact and asymptotic weighted logrank tests for interval censored data: the interval R package. J Stat Softw 2010;36:1-34.
35. East African/British Medical Research Council. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972;1:1079-1085.
36. East African/British Medical Research Council. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1974;2: 1100-1106.
37. East African/British Medical Research Council. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report: Third East African/British Medical Research Councils study. Am Rev Respir Dis 1978;118:39-48.
38. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months. Tubercle 1979;60:201-210.
39. Hong Kong Chest Service/British Medical Research Council. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 1981;1:171-174.
40. British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. Am Rev Respir Dis 1982;126:460-462.
41. Combs DL, O'Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990;112:397-406.
42. Boeree M, Diacon A, Dawson R; PanACEA Consortium. What is the 'right' dose of rifampin? Presented at the 20th Conference on Retroviruses and Opportunistic Infections. March 3-6, 2013, Atlanta, GA. Abstract 148LB.
43. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ; REMoxTB Consortium. Fourmonth moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014;371:1577-1587.
44. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, Odhiambo J, Amukoye E, Bah B, Kassa F, et al.; OFLOTUB/Gatifloxacin for Tuberculosis Project. A four-month gatifloxacincontaining regimen for treating tuberculosis. N Engl J Med 2014;371: 1588-1598.
45. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, et al.; Gatifloxacin for TB (OFLOTUB) study team. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008;12:128-138.
46. Conde MB, Efron A, Loredo C, De Souza GR, Grac¸a NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a doubleblind, randomised, controlled phase II trial. Lancet 2009;373: 1183-1189.
47. Dooley KE, Savic R, Park J-G, Cramer Y, Hafner R, Janik J, Marzinke MA, Weiner M, Dorman S, Haas DW, et al. Safety and pharmacokinetics of novel dosing strategies to increase rifapentine exposures for TB: preliminary results from ACTG Study A5311. Presented at the 21st Conference on Retroviruses and Opportunistic Infections. March 3-6, 2014, Boston, MA. Abstract 816.